CJC-1295 + ipamorelin is not anti-aging proof
No. CJC-1295 and ipamorelin can move growth-hormone-related markers in limited human pharmacology research, but that does not prove the stack improves fat loss, muscle gain, sleep, recovery, or aging outcomes.
No. CJC-1295 and ipamorelin can move growth-hormone-related markers in limited human pharmacology research, but that does not prove the stack improves fat loss, muscle gain, sleep, recovery, or aging outcomes.
Small CJC-1295 studies measured GH and IGF-1 marker effects in controlled settings, while ipamorelin evidence is mostly older human volunteer pharmacology and early GH-secretagogue research. FDA lists CJC-1295 and ipamorelin acetate with peptide-impurity, immunogenicity, API-characterization, limited clinical-data or safety-information, and serious-adverse-event concerns. WADA/USADA context also keeps growth-hormone secretagogues in tested-athlete territory.
What to do instead
Do not treat a growth-hormone peptide stack as a body-recomposition, sleep, recovery, or anti-aging plan because a lab marker moved. Endocrine disease, diabetes, cancer history, cardiovascular risk, pregnancy, medication use, sleep disorders, unexplained symptoms, product identity, route, purity, adverse-event reporting, and tested sport all belong in clinician or anti-doping context.
“CJC-1295 and ipamorelin safely boost growth hormone for fat loss, muscle, sleep, and anti-aging.”
At a glance
- Status: published
- Topic: Supplements
- Author: No Lies Lifting Editorial